精神分裂症与双相障碍的线粒体功能通路特征具有诊断和细胞类型特异性
该研究利用背外侧前额叶皮层灰质及第3、5层锥体神经元的转录组数据,发现精神分裂症组41%线粒体相关基因差异表达且83%下调、富集于三个能量产生通路,双相障碍组仅8%差异表达且无通路富集;此模式在锥体神经元中重现,且差异不能归因于抗精神病药物。
要点
- 精神分裂症背外侧前额叶皮层线粒体基因广泛下调并富集能量产生通路,双相障碍无此 pattern。
- 差异表达模式在锥体神经元中同样存在,提示细胞类型特异性。
- 基因表达改变非抗精神病药物所致,能量产生通路下调或为治疗靶点。
核心结论
- 精神分裂症与双相障碍在背外侧前额叶皮层的线粒体改变不相似,精神分裂症以能量产生基因选择性协调下调为特征。
研究设计与样本
- 获取精神分裂症或双相障碍受试者背外侧前额叶皮层灰质及第3、5层锥体神经元的线粒体功能通路基因集转录组数据。
- 分析采用差异表达基因识别及功能通路富集与加权基因共表达网络分析双策略。
- 在长期暴露于抗精神病药物的猴子中重复分析以确定药物对线粒体相关基因表达的影响。
主要发现
- 背外侧前额叶皮层灰质中,精神分裂症组41%线粒体相关基因差异表达,双相障碍组为8%。
- 精神分裂症组83%差异表达基因表达降低,并显著富集于三个能量产生功能通路。
- 双相障碍组差异表达基因未富集于功能通路。
- 上述疾病相关模式在锥体神经元中同样被识别。
- 基因表达改变未破坏共表达模块,且差异表达基因不能归因于抗精神病药物。
临床怎么用
- 精神分裂症患者背外侧前额叶皮层能量产生通路基因选择性下调,增强锥体神经元放电活动或可作为治疗靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The shared risk factors and clinical features in schizophrenia and bipolar disorder may be linked via mitochondrial dysfunction. However, the severity of mitochondrial dysfunction, and/or the specific mitochondrial functional pathways affected, may differ between diagnoses, especially at the level of individual cell types. METHODS: Transcriptomic profiling data for a gene set indexing mitochondrial functional pathways were obtained for dorsolateral prefrontal cortex (DLPFC) gray matter and layer 3 and layer 5 pyramidal neurons of subjects with schizophrenia or bipolar disorder. Analyses were conducted using a dual strategy: identification of differentially expressed genes (DEGs) and their functional pathway enrichment, and application of weighted gene coexpression network analysis. These analyses were repeated in monkeys chronically exposed to antipsychotic drugs to determine their effect on mitochondrial-related gene expression. RESULTS: In DLPFC gray matter, 41% of mitochondrial-related genes were differentially expressed in the schizophrenia group, whereas 8% were differentially expressed in the bipolar group. In the schizophrenia group, 83% of DEGs showed lower expression, and these were significantly enriched for three functional pathways, each indexing energy production. DEGs in the bipolar disorder group were not enriched for functional pathways. This disease-related pattern of findings was also identified in pyramidal neurons. None of the gene expression alterations disrupted coexpression modules, and DEGs were not attributable to antipsychotic medications. CONCLUSIONS: Schizophrenia and bipolar disorder do not appear to share similar mitochondrial alterations in the DLPFC. The selective and coordinated down-regulation of energy production genes in schizophrenia is consistent with the effects of chronic reductions in pyramidal neuron firing, and enhancement of this activity may serve as a therapeutic target.
引用
- Glausier JR, Enwright JF, Lewis DA, et al. Diagnosis- and Cell Type-Specific Mitochondrial Functional Pathway Signatures in Schizophrenia and Bipolar Disorder. Am J Psychiatry. 2020. PMID: 33115248. doi:10.1176/appi.ajp.2020.19111210
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。